Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Investigating the Role of B-cells in Durable Complete Responses to Immunotherapy in Head and Neck Cancer

Award Number: R01CA292622
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2026
PERIOD OF PERFORMANCE END DATE: 03/31/2031

Group Awards By:

View Award Description

Investigating the Role of B-cells in Durable Complete Responses to Immunotherapy in Head and Neck Cancer - Project Summary While response rates to Checkpoint Blockade Immunotherapy (CBI) in Head and Neck Squamous Cell Carcinoma (HNSCC) are generally low, approximately 3-5% of patients show durable complete responses (dCR) and remain disease-free for at least two years following treatment. The mechanisms underlying these exceptional responses are unknown and may hold great promise for the development and refinement of immunotherapies. Remarkably, our recent work has determined that B-cell anti-tumor activity is associated with complete responses to CBI in HNSCC. However, the mechanisms underlying this increase in B-cell-mediated antibody activity, and the pathways by which B cells contribute to tumor control are understudied. The primary long-term goal of this project is to better understand the role of B cells in complete responses to CBI in HNSCC and thus improve immunotherapeutic approaches and increase complete response rates. The overall objectives of this application are to (i) test novel agents to harness and enhance B-cell mediated anti-tumor immunity, (ii) dissect the mechanism of action of B-cell mediated tumor control; and iii) define the specificity and identity of B-cell antibody profiles from patients with dCRs in HNSCC. The central hypothesis is that adaptive B cell activity is critically involved in complete responses to CBI in HNSCC and will be tested with three specific aims. Specific Aim 1 will determine the effects of CBI on B-cell activation and whether combinations of specific B-cell activators enhance anti-tumor immune responses and tumor control. Specific Aim 2 will identify B cell subtypes that mediate anti-tumor immunity, and dissect the mechanism of action of B- cells in orthotopic models of HNSCC. Specific Aim 3 will define the specificity and identify novel B-cell antibody repertoires that drive durable complete responses in HNSCC patients. The research proposed in this application is innovative due to the focus on durable and complete responses to cancer immunotherapy and the exploration of the mechanisms underlying these exceptional responses associated with the critical yet understudied role of B cells. The research is significant because it will identify specific B-cell agonists that can be used to enhance tumor control with CBI or XRT, elucidate the mechanism of action of B-cells and critical B-cell subtypes; and establish whether B-cell mediated antibody responses drive exceptional completed responses in HNSCC patients. Ultimately, these findings can be directly translated to improve outcomes for HNSCC patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $650,597 )
2026	2026	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Cancer Treatment Research	000	1	3/16/2026	NEW	$650,597
														Subtotal = $650,597

Grand Total All Awards = $650,597

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Investigating the Role of B-cells in Durable Complete Responses to Immunotherapy in Head and Neck Cancer

Award Number: R01CA292622

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2026

PERIOD OF PERFORMANCE END DATE: 03/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer